Pfizer’s ADCETRIS regimen produces clinically meaningful improvement in overall survival in patients with DLBCL
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Subscribe To Our Newsletter & Stay Updated